An evidence-based review of the clinical use of sertraline in mood and anxiety disorders
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Sertraline is a selective serotonin reuptake inhibitor that has been used and studied extensively throughout the world and found to be safe and well tolerated in numerous patient populations, including those with either psychiatric and/or medical comorbidities. Randomized clinical trials have shown that it is an effective treatment for depressive and anxiety disorders and its efficacy is unaffected by psychiatric comorbidity. In non-comorbid patients, sertraline is effective for the acute treatment of major depressive disorders and prevention of relapse or recurrence. It is effective for acute treatment and longer-term management of social anxiety disorder, posttraumatic stress disorder,panic disorder, and generalized anxiety disorder. In adults and in pediatric patients, it is an effective short-term and long-term treatment for obsessive compulsive disorder.Sertraline has a good tolerability profile and has low fatal toxicity. In summary, sertraline is as effective as other antidepressants over a wide range of indications but may offer tolerability benefits as well as efficacy in patients with psychiatric and/or medical comorbidities and certain subtypes of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
Magee, W. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020077009 · Cited by 996
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., & Farfel, G. M. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.485 · Cited by 470
Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders
Regier, D. A., Rae, D. S., Narrow, W. E., Kaelber, C. T., & Schatzberg, A. F. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293483 · Cited by 407
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398 · cited 1×
“…Alzheimer’s patients were classed on depressive scales as full or partial responders compared with placebo-treated patients (P = 0.007), and they had significantly better ratings on activities of daily living, behavioral disturbance, and caregiver distress (Pr 0.04) (Lyketsos et al., 2003).”
BackgroundInfluentialDetke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · cited 1×
“A placebo-controlled study with the SNRI duloxetine (Detke et al., 2002) showed that duloxetine was more effective than placebo in treating patients with MDD.”
MethodArroll, B. (2005) · The Annals of Family Medicine · doi:10.1370/afm.349 · Cited by 351 · cited 3×
“The superior safety profile of SSRIs is well established and is confirmed in all of these metaanalyses (Geddes et al., 2000; Macgillivray et al., 2003; Arroll et al., 2005).”
BackgroundResultCarney, R. M., Blumenthal, J. A., Freedland, K. E., Youngblood, M., Veith, R. C., Burg, M. M., Cornell, C., Saab, P. G., Kaufmann, P. G., Czajkowski, S. M., et al. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000133362.75075.a6 · Cited by 291 · cited 1×
“Survival after acute myocardial infarction among patients with depression and/or low perceived social support was investigated by the Enhancing Recovery in Coronary Heart Disease study (Carney et al., 2004).”
MethodMacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., & Crombie, I. (2003) · BMJ · doi:10.1136/bmj.326.7397.1014 · Cited by 265 · cited 2×
“The superior safety profile of SSRIs is well established and is confirmed in all of these metaanalyses (Geddes et al., 2000; Macgillivray et al., 2003; Arroll et al., 2005).”
BackgroundResultBrowne, G., Steiner, M., Roberts, J., Gafni, A., Byrne, C., Dunn, E., Bell, B., Mills, M., Chalklin, L., Wallik, D., et al. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00343-3 · Cited by 199 · cited 1×
“An augmentation of response to sertraline by interpersonal psychotherapy was also reported in a 2-year, naturalistic study of primary-care patients (Browne et al., 2002), but not in a study of adolescents (12–18 years).”
BackgroundClinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00210-8 · Cited by 196
Otto, M. W., Hinton, D., Korbly, N. B., Chea, A., Ba, P., Gershuny, B. S., & Pollack, M. H. (2003) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(03)00032-9 · Cited by 194
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183 · cited 2×
“Side effect and safety profile Extensive literature suggests that sertraline is a welltolerated antidepressant agent when compared with either other SSRIs or TCAs (for a comprehensive review, see Goldstein and Goodnick, 1998; Goodnick and Goldstein, 1998).”
BackgroundMichelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · cited 2×
“In a study, patients who were being successfully treated with fluoxetine, paroxetine, or sertraline for at least 4 months suspended their medication for a period of 5 days (Michelson et al., 2000).”
BackgroundPRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171 · cited 1×
“In addition, Price investigated serotonin withdrawal syndrome in fluoxetine, fluvoxamine, paroxetine and sertraline (Price et al., 1996), by searching the UK database of adverse reactions for each drug, and reported that the safety profile of the four drugs was similar.”
BackgroundGoldstein, B. J., & Goodnick, P. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003041 · Cited by 171 · cited 1×
“Side effect and safety profile Extensive literature suggests that sertraline is a welltolerated antidepressant agent when compared with either other SSRIs or TCAs (for a comprehensive review, see Goldstein and Goodnick, 1998; Goodnick and Goldstein, 1998).”
BackgroundA Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
Newhouse, P. A., Krishnan, K. R. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., & Clary, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0804 · Cited by 163 · cited 1×
“5) (Newhouse et al., 2000).”
Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial
Haug, T. T., Blomhoff, S., Hellstrøm, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.312 · Cited by 151 · cited 1×
“Maintenance of treatment effect was measured by Haug et al. (2003).”
MethodSir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1015 · Cited by 129 · cited 2×
“A comparative study of sertraline with venlafaxine XR showed sertraline to be associated with a lower symptom burden during treatment discontinuation and a reduced risk of increase in blood pressure(Sir et al., 2005).”
BackgroundResultDouble-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
Aguglia, E., Casacchia, M., Cassano, G. B., Faravelli, C., Ferrari, G., Giordano, P., Pancheri, P., Ravizza, L., Trabucchi, M., Bolino, F., et al. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00010 · Cited by 115
Sousa, M. B., Isolan, L. R., Oliveira, R. R., Manfro, G. G., & Cordioli, A. V. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0717 · Cited by 110 · cited 1×
“When compared with CBT, 100 mg/day of sertraline was found to be less effective in the treatment of OCD, as measured by the rate of symptom reduction, intensity reduction of compulsions, and percentage of patients who obtained full remission (Sousa et al., 2006).”
MethodWalker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84 · cited 3×
“Longer-term treatment of social anxiety disorder using sertraline has been investigated in a study by Walker et al. (2000).”
BackgroundLépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83 · cited 2×
“Similarly, in a study in which patients were treated with different doses of sertraline, 50 or 100 mg, recurrence was significantly less frequent in the sertraline groups compared with placebo (50 mg, 16.8%; 100 mg, 17.0%; placebo, 33.3%; P < 0.05) (Lepine et al., 2004).”
BackgroundResultInfluentialSertraline treatment of panic disorder: results of a long-term study
Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., & Ota, K. Y. (2001) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2001.00263.x · Cited by 79 · cited 1×
“Long-term efficacy of sertraline has been assessed by 52 weeks of open-label sertraline treatment followed by a 28-week, double-blind, placebo-controlled discontinuation trial (Rapaport et al., 2001).”
BackgroundWilson, K. C. M., Mottram, P. G., Ashworth, L., & Abou-Saleh, M. T. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.492 · Cited by 74 · cited 1×
“In contrast, one study in community-dwelling patients aged Z 65 years found no long-term benefit in depressive episode recurrence with sertraline compared with placebo over a 2-year, double-blind period (Wilson et al., 2003).”
ResultLépine, J. P., Goger, J., Blashko, C., Probst, C., Moles, M.-F., Kosolowski, J., Scharfetter, B., & Lane, R. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00003 · Cited by 19
Cited by
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
A practical approach to prescribing antidepressants
Shultz, E., & Malone, D. A. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12133 · Cited by 27
Willard, S. L., Uberseder, B., Clark, A., Daunais, J. B., Johnston, W. D., Neely, D., Massey, A., Williamson, J. D., Kraft, R. A., Bourland, J. D., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.011 · Cited by 25
“Sertraline is widely prescribed and has been shown to be efficacious for the treatment of anxiety disorders in people (Baldwin, Woods, Lawson, & Taylor, 2011; Sheehan & Kamijima, 2009).”
Background
Metadata
- Authors
- Sheehan, D. V., & Kamijima, K.
- Venue
- International Clinical Psychopharmacology
- Published
- 2009-03
- Volume
- 24
- Issue
- 2
- Pages
- 43-60
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2169865323
- Cited by
- 39
- References
- 27
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.